A detailed history of Rubric Capital Management LP transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Rubric Capital Management LP holds 15,307,347 shares of MREO stock, worth $55.6 Million. This represents 1.75% of its overall portfolio holdings.

Number of Shares
15,307,347
Previous 15,307,347 -0.0%
Holding current value
$55.6 Million
Previous $55.1 Million 14.17%
% of portfolio
1.75%
Previous 1.63%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.58 - $4.25 $4.53 Million - $7.46 Million
1,754,350 Added 12.94%
15,307,347 $55.1 Million
Q4 2023

Feb 13, 2024

BUY
$1.19 - $2.42 $2.3 Million - $4.69 Million
1,936,877 Added 16.67%
13,552,997 $31.3 Million
Q2 2023

Aug 11, 2023

BUY
$0.79 - $1.43 $987,500 - $1.79 Million
1,250,000 Added 12.06%
11,616,120 $15.3 Million
Q3 2022

Nov 14, 2022

SELL
$0.82 - $1.73 $5.24 Million - $11.1 Million
-6,390,000 Reduced 38.14%
10,366,120 $8.93 Million
Q2 2022

Aug 15, 2022

BUY
$0.33 - $1.69 $579,519 - $2.97 Million
1,756,120 Added 11.71%
16,756,120 $18.8 Million
Q1 2022

May 13, 2022

BUY
$1.04 - $1.7 $88,975 - $145,440
85,553 Added 0.57%
15,000,000 $16.8 Million
Q4 2021

Feb 14, 2022

BUY
$1.51 - $2.59 $5.46 Million - $9.36 Million
3,614,447 Added 31.99%
14,914,447 $23.9 Million
Q3 2021

Nov 12, 2021

BUY
$2.2 - $3.17 $12.4 Million - $17.9 Million
5,639,392 Added 99.63%
11,300,000 $27.3 Million
Q2 2021

Aug 13, 2021

BUY
$2.94 - $4.08 $8.07 Million - $11.2 Million
2,745,747 Added 94.2%
5,660,608 $17.9 Million
Q1 2021

May 14, 2021

BUY
$2.6 - $4.43 $2.76 Million - $4.7 Million
1,061,444 Added 57.27%
2,914,861 $9.82 Million
Q4 2020

Feb 16, 2021

BUY
$1.95 - $3.6 $3.61 Million - $6.67 Million
1,853,417 New
1,853,417 $6.64 Million

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $454M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Rubric Capital Management LP Portfolio

Follow Rubric Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rubric Capital Management LP with notifications on news.